Evidence Hub

Cavernosal Uric Acid Level in Vasculogenic Erectile Dysfunction Patients Before and After Allopurinol Alone Versus Allopurinol Plus Daily Tadalafil 5 mg: Comparative Study

Al-Azhar International Medical Journal /Al-Azhar International Medical Journal, 2024

80 participants

Abstract

Background: Erectile dysfunction (ED) is the inability to sustain an erection that is firm enough to engage in satisfactory sexual intercourse. Previous literature reported a link between hyperuricemia and ED and others found Allopurinol could reduce the risk of ED in patients with hyperuricemia. Aim: We aim in our study to assess the impact of hyperuricemia on ED and the effect of Allopurinol on this population either alone or with Tadalafil. Patients and methods: We recruited a sample of 80 participants. Patients with vasculogenic ED and hyperuricemia underwent uric acid (UA) measurement before and after receiving Allopurinol for 2 months, then after receiving Allopurinol plus Tadalafil daily dose for another 2 months. The participants were divided into three groups based on their baseline International Index of Erectile Function questionnaire (IIEF5): mild to moderate ED, mild ED, and no ED. Results: Baseline UA levels and IIEF5 showed significant variation among all groups (P 0.05). Participants’ comparison at the different time points revealed highly significant differences in all the variables being compared (P < 0.001). Conclusion: Substantial differences were observed in UA levels and IIEF5 scores at baseline, 2 months, and 4 months, indicating the efficacy of Allopurinol alone and Allopurinol plus Tadalafil in decreasing UA levels and improvement of ED.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free